Skip to main content

Advertisement

SpringerLink
Log in

Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study

  • Original Article
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

Summary

Using a nationwide database from the Korean National Health Insurance Service, this study showed that once-monthly oral ibandronate (150 mg) had better anti-fracture efficacy than once-monthly oral risedronate (150 mg), as seen on assessing overall and non-vertebral fractures among Korean elderly women with osteoporosis.

Introduction

Once-monthly oral bisphosphonates have been used widely without appropriate comparison. Therefore, we aimed to compare the anti-fracture efficacy of once-monthly ibandronate (150 mg) and once-monthly risedronate (150 mg).

Methods

We conducted a retrospective cohort study among Korean women aged ≥ 60 years from 2006 to 2015 using a nationwide database from the National Health Insurance Service Senior Cohort. The primary outcome was the first occurrence of fracture related to osteoporosis after the initial prescription of bisphosphonates. A Cox proportional model was used to estimate the incidence rate ratios (IRRs) and 95% confidence intervals (CIs) for overall and site-specific fractures between the two treatments, after adjusting for possible confounding factors.

Results

After propensity score matching, the ibandronate and risedronate groups, with 3454 patients each, were assembled from 36,701 new once-monthly ibandronate or risedronate users. After 4 years of follow-up, the ibandronate group had significantly lower incidence rates of overall and non-vertebral fractures than the risedronate group (IRR 0.822, 95% CI 0.698–0.968, P = 0.919 and IRR 0.798, 95% CI 0.647–0.985, P = 0.036, respectively).

Conclusions

Once-monthly ibandronate (150 mg) shows better anti-fracture efficacy than once-monthly risedronate (150 mg). However, further large-scale studies are required to confirm our findings and to determine site-specific differences, especially regarding the vertebral and hip areas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Harvey N, Dennison E, Cooper C (2010) Osteoporosis: impact on health and economics. Nat Rev Rheumatol 6:99–105

    Article  PubMed  Google Scholar 

  2. Johnell O (1997) The socioeconomic burden of fractures: today and in the 21st century. Am J Med 103:S20–S26

    Article  Google Scholar 

  3. Global Osteoporosis Drugs Market Size, Share, Development, Growth and Demand Forecast to 2022 – Industry Insights by Drug Class (Bisphosphonates, Parathyroid Hormone Therapy, Selective Estrogen Receptor Modulators, Rank Ligand Inhibitor, Calcitonin and Others. https://www.psmarketresearch.com/market-analysis/osteoporosis-drugs-market. Accessed Apr 20 2018

  4. Recker RR, Gallagher R, MacCosbe PE (2005) Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 80:856–861

    Article  PubMed  Google Scholar 

  5. Nancollas GH, Tang R, Phipps RJ, Henneman Z, Gulde S, Wu W, Mangood A, Russell RG, Ebetino FH (2006) Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone 38:617–627

    Article  CAS  Google Scholar 

  6. Kastelan D, Lozo P, Stamenkovic D, Miskic B, Vlak T, Kolak Z, Milas Ahic J, Altabas V, Crncevic Orlic Z, Korsic M (2009) Preference for weekly and monthly bisphosphonates among patients with postmenopausal osteoporosis: results from the Croatian PROMO study. Clin Rheumatol 28:321–326

    Article  PubMed  Google Scholar 

  7. Siris ES, Selby PL, Saag KG, Borgstrom F, Herings RM, Silverman SL (2009) Impact of osteoporosis treatment adherence on fracture rates in North America and Europe. Am J Med 122:S3–S13

    Article  PubMed  Google Scholar 

  8. Brenner BG, Routy JP, Petrella M, Moisi D, Oliveira M, Detorio M, Spira B, Essabag V, Conway B, Lalonde R, Sekaly RP, Wainberg MA (2002) Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 76:1753–1761

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis: 2001 update. American College of Rheumatology Ad Hoc Committee on glucocorticoid-induced osteoporosis. Arthritis Rheum 44:1496–1503

  10. Yoo JH, Moon SH, Ha YC, Lee DY, Gong HS, Park SY, Yang KH (2015) Osteoporotic fracture: 2015 position statement of the Korean Society for Bone and Mineral Research. J Bone Metab 22:175–181

    Article  PubMed  PubMed Central  Google Scholar 

  11. Szulc P, Bouxsein M (2011) Overview of Osteoporosis. Epidemiology and Clinical Management. International Osteoporosis Foundation Vertebral Fracture Initiative Resource Document Part I. https://www.iofbonehealth.org/sites/default/files/PDFs/Vertebral%20Fracture%20Initiative/IOF_VFI-Part_I-Manuscript.pdf. Accessed 19 June 2018

  12. Ko YJ, Kim JY, Lee J, Song HJ, Kim JY, Choi NK, Park BJ (2014) Levothyroxine dose and fracture risk according to the osteoporosis status in elderly women. J Prev Med Public Health 47:36–46

    Article  PubMed  PubMed Central  Google Scholar 

  13. Faries DE, Leon AC, Maria HJ, Obenchain RL (2010) Analysis of observational health care data using SAS. SAS Institute Inc., Cary

    Google Scholar 

  14. Kleinbaum DG, Klein M (2012) Evaluating the proportional hazards assumption. In: Survival analysis: a self-learning text, 3rd edn. Springer, New York, pp 161–197

    Google Scholar 

  15. Russell RG, Watts NB, Ebetino FH, Rogers MJ (2008) Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int 19:733–759

    Article  CAS  PubMed  Google Scholar 

  16. Recker R, Stakkestad JA, Chesnut CH 3rd, Christiansen C, Skag A, Hoiseth A, Ettinger M, Mahoney P, Schimmer RC, Delmas PD (2004) Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34:890–899

    Article  CAS  PubMed  Google Scholar 

  17. Chesnut CH 3rd, Skag A, Christiansen C et al (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249

    Article  CAS  PubMed  Google Scholar 

  18. Nakamura T, Nakano T, Ito M, Hagino H, Hashimoto J, Tobinai M, Mizunuma H, Group MS (2013) Clinical efficacy on fracture risk and safety of 0.5 mg or 1 mg/month intravenous ibandronate versus 2.5 mg/day oral risedronate in patients with primary osteoporosis. Calcif Tissue Int 93:137–146

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Cranney A, Wells GA, Yetisir E, Adami S, Cooper C, Delmas PD, Miller PD, Papapoulos S, Reginster JY, Sambrook PN, Silverman S, Siris E, Adachi JD (2009) Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data. Osteoporos Int 20:291–297

    Article  CAS  PubMed  Google Scholar 

  20. Nakai K, Tobinai M, Hashimoto J, Iida S, Kawanishi T (2016) The optimal oral dose selection of ibandronate in Japanese patients with osteoporosis based on pharmacokinetic and pharmacodynamic properties. Eur J Drug Metab Pharmacokinet 41:139–147

    Article  CAS  PubMed  Google Scholar 

  21. Shiraki M, Fukunaga M, Kushida K, Kishimoto H, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H (2003) A double-blind dose-ranging study of risedronate in Japanese patients with osteoporosis (a study by the risedronate late phase II research group). Osteoporos Int 14:225–234

    Article  CAS  PubMed  Google Scholar 

  22. Delmas PD, McClung MR, Zanchetta JR et al (2008) Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis. Bone 42:36–42

    Article  CAS  PubMed  Google Scholar 

  23. Harris ST, Watts NB, Genant HK, McKeever C, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral efficacy with risedronate therapy (VERT) study group. JAMA 282:1344–1352

    Article  CAS  Google Scholar 

  24. Reginster J, Minne HW, Sorensen OH et al (2000) Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral efficacy with risedronate therapy (VERT) study group. Osteoporos Int 11:83–91

    Article  CAS  Google Scholar 

  25. Lindsay R (2007) Beyond clinical trials: the importance of large databases in evaluating differences in the effectiveness of bisphosphonate therapy in postmenopausal osteoporosis. Bone 40:S32–S35

    Article  CAS  Google Scholar 

  26. Dowd R, Recker RR, Heaney RP (2000) Study subjects and ordinary patients. Osteoporos Int 11:533–536

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

This study was supported by Wonkwang University in 2017.

Author information

Authors and Affiliations

  1. Department of Family Medicine, Wonkwang University School of Medicine, Wonkwang University Sanbon Hospital, 321, Sanbon-ro, Gunpo-si, 15865, Gyeonggi-do, Republic of Korea

    Dong Ryul Lee & Jungun Lee

Authors
  1. Dong Ryul Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jungun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Dong Ryul Lee.

Ethics declarations

Conflicts of interest

None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lee, D.R., Lee, J. Comparison of the efficacy between once-monthly oral ibandronate and risedronate among Korean women with osteoporosis: a nationwide population-based study. Osteoporos Int 30, 659–666 (2019). https://doi.org/10.1007/s00198-018-4778-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-018-4778-0

Keywords

Search

Navigation